ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they d...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 March 2024
|
| In: |
Annals of hematology
Year: 2024, Jahrgang: 103, Heft: 7, Pages: 2299-2310 |
| ISSN: | 1432-0584 |
| DOI: | 10.1007/s00277-024-05665-4 |
| Online-Zugang: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1007/s00277-024-05665-4 Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00277-024-05665-4 Resolving-System, kostenfrei: https://doi.org/10.25673/117314 
|
| Verfasserangaben: | Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, et al. ; authors and affiliations: Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer-Ausch, Olga Cerna, Ana-Manuela Crisan, Andreas Johannes Reiter [und viele weitere] |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1885689020 | ||
| 003 | DE-627 | ||
| 005 | 20241205140832.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-024-05665-4 |2 doi | |
| 024 | 7 | |a 10.25673/117314 |2 doi | |
| 035 | |a (DE-627)1885689020 | ||
| 035 | |a (DE-599)KXP1885689020 | ||
| 035 | |a (OCoLC)1475287562 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kiladjianm, Jean-Jacques |e VerfasserIn |0 (DE-588)1344995160 |0 (DE-627)1905733119 |4 aut | |
| 245 | 1 | 0 | |a ROP-ET |b a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options |c Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, et al. ; authors and affiliations: Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer-Ausch, Olga Cerna, Ana-Manuela Crisan, Andreas Johannes Reiter [und viele weitere] |
| 264 | 1 | |c 4 March 2024 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.10.2024 | ||
| 520 | |a Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they do not modify the natural history of the disease and hence, have no impact on disease progression. Ropeginterferon alfa-2b (trade name BESREMi®), a novel, monopegylated interferon alfa-2b with an extended administration interval, has demonstrated a robust and sustained efficacy in polycythemia vera (PV) patients. Given the similarities in disease pathophysiology and treatment goals, ropeginterferon alfa-2b holds promise as a treatment option for ET. The ROP-ET trial is a prospective, multicenter, single-arm phase III study that includes patients with ET who are intolerant or resistant to, and/or are ineligible for current therapies, such as hydroxyurea (HU), anagrelide (ANA), busulfan (BUS) and pipobroman, leaving these patients with limited treatment options. The primary endpoint is a composite response of hematologic parameters and disease-related symptoms, according to modified European LeukemiaNet (ELN) criteria. Secondary endpoints include improvements in symptoms and quality of life, molecular response and the safety profile of ropeginterferon alfa-2b. Over a 3-year period the trial assesses longer term outcomes, particularly the effects on allele burden and clinical outcomes, such as disease-related symptoms, vascular events and disease progression. No prospective clinical trial data exist for ropeginterferon alfa-2b in the planned ET study population and this study will provide new findings that may contribute to advancing the treatment landscape for ET patients with limited alternatives. | ||
| 540 | |q DE-3 |a Namensnennung 4.0 International |f CC BY 4.0 |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 650 | 4 | |a Disease modification | |
| 650 | 4 | |a Essential thrombocythemia (ET) | |
| 650 | 4 | |a Myeloproliferative neoplasms (MPNs) | |
| 650 | 4 | |a Phase III | |
| 650 | 4 | |a ROP-ET | |
| 650 | 4 | |a Ropeginterferon alfa-2b | |
| 700 | 1 | |a Marin, Francisca Ferrer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Al-Ali, Haifa Kathrin |d 1963- |e VerfasserIn |0 (DE-588)1033091529 |0 (DE-627)740787667 |0 (DE-576)380735504 |4 aut | |
| 700 | 1 | |a Alvarez-Larrán, Alberto |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beggiato, Eloise |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bieniaszewska, Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Breccia, Massimo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Buxhofer-Ausch, Veronika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cerna, Olga |e VerfasserIn |4 aut | |
| 700 | 1 | |a Crisan, Ana-Manuela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reiter, Andreas |d 1964- |e VerfasserIn |0 (DE-588)172629551 |0 (DE-627)697563766 |0 (DE-576)133488594 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Berlin : Springer, 1991 |g 103(2024), 7, Seite 2299-2310 |h Online-Ressource |w (DE-627)253389852 |w (DE-600)1458429-3 |w (DE-576)072283157 |x 1432-0584 |7 nnas |a ROP-ET a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options |
| 773 | 1 | 8 | |g volume:103 |g year:2024 |g number:7 |g pages:2299-2310 |g extent:12 |a ROP-ET a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00277-024-05665-4 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s00277-024-05665-4 |x Verlag |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.25673/117314 |x Resolving-System |z kostenfrei |
| 951 | |a AR | ||
| 992 | |a 20241015 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 172629551 |a Reiter, Andreas |m 172629551:Reiter, Andreas |d 60000 |d 61200 |e 60000PR172629551 |e 61200PR172629551 |k 0/60000/ |k 1/60000/61200/ |p 33 | ||
| 999 | |a KXP-PPN1885689020 |e 4595486316 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"4 March 2024","dateIssuedKey":"2024"}],"id":{"doi":["10.1007/s00277-024-05665-4","10.25673/117314"],"eki":["1885689020"]},"note":["Gesehen am 15.10.2024"],"person":[{"role":"aut","given":"Jean-Jacques","family":"Kiladjianm","display":"Kiladjianm, Jean-Jacques"},{"role":"aut","given":"Francisca Ferrer","family":"Marin","display":"Marin, Francisca Ferrer"},{"display":"Al-Ali, Haifa Kathrin","family":"Al-Ali","role":"aut","given":"Haifa Kathrin"},{"display":"Alvarez-Larrán, Alberto","role":"aut","given":"Alberto","family":"Alvarez-Larrán"},{"role":"aut","given":"Eloise","family":"Beggiato","display":"Beggiato, Eloise"},{"display":"Bieniaszewska, Maria","role":"aut","given":"Maria","family":"Bieniaszewska"},{"display":"Breccia, Massimo","given":"Massimo","role":"aut","family":"Breccia"},{"display":"Buxhofer-Ausch, Veronika","role":"aut","given":"Veronika","family":"Buxhofer-Ausch"},{"family":"Cerna","role":"aut","given":"Olga","display":"Cerna, Olga"},{"display":"Crisan, Ana-Manuela","given":"Ana-Manuela","role":"aut","family":"Crisan"},{"given":"Andreas","role":"aut","family":"Reiter","display":"Reiter, Andreas"}],"title":[{"title":"ROP-ET","title_sort":"ROP-ET","subtitle":"a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options"}],"language":["eng"],"recId":"1885689020","type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"note":["Gesehen am 24.04.2025","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 80.2001: Supplement"],"title":[{"subtitle":"organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie","title":"Annals of hematology","title_sort":"Annals of hematology"}],"disp":"ROP-ET a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment optionsAnnals of hematology","origin":[{"dateIssuedDisp":"1991-","publisher":"Springer","dateIssuedKey":"1991","publisherPlace":"Berlin ; Heidelberg ; New York"}],"physDesc":[{"extent":"Online-Ressource"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"titleAlt":[{"title":"Hematology"}],"pubHistory":["62, 1 (Februrary 1991)-"],"id":{"zdb":["1458429-3"],"issn":["1432-0584"],"eki":["253389852"]},"part":{"pages":"2299-2310","volume":"103","extent":"12","issue":"7","text":"103(2024), 7, Seite 2299-2310","year":"2024"},"recId":"253389852"}],"name":{"displayForm":["Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, et al. ; authors and affiliations: Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer-Ausch, Olga Cerna, Ana-Manuela Crisan, Andreas Johannes Reiter [und viele weitere]"]},"physDesc":[{"extent":"12 S."}]} | ||
| SRT | |a KILADJIANMROPET4202 | ||